<p><strong>融资包括医疗专注投资者与现有股东的参与</strong></p>
<p>多伦多，2025 年 12 月 19 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp.（纳斯达克：PROF；多伦多证券交易所：PRN）</strong>（“Profound” 或 “公司”）今天宣布以每股 7.00 美元的价格出售 5,142,857 股普通股，进行注册直接发行，并计划在加拿大进行后续私人配售，最多 571,428 股普通股，购买价格为每股 7.00 美元，预计总收益可达 4000 万美元。</p>
<p>此次注册直接发行被结构化为一种简单的股权投资，没有认股权证覆盖，由医疗专注投资者与现有股东共同主导。该部分发行预计将在 2025 年 12 月 22 日（星期一）左右完成，具体取决于满足惯常的交割条件。</p>
<p>公司预计此次发行的总收益约为 3600 万美元，未扣除配售代理费用和公司需支付的其他发行费用。公司打算将发行的净收益用于销售和市场扩展、营运资金、研发、战略交易和一般公司用途。</p>
<p><strong>Konik Capital Partners, LLC，T.R. Winston and Company, LLC 的一个部门，作为此次发行的独家配售代理。</strong></p>
<p>此次发行是根据已生效的 S-3 表格（文件编号 333-291516）进行的，该表格已于 2025 年 12 月 4 日向证券交易委员会（“SEC”）提交并获得批准。此次发行仅通过补充招股说明书和附带的基础招股说明书进行，这些文件构成有效的架构注册声明的一部分。与此次发行相关的补充招股说明书和附带的基础招股说明书将提交给 SEC，并可在 SEC 网站 http://www.sec.gov 上获取。此外，当可用时，补充招股说明书和附带的基础招股说明书的电子副本可从 Konik Capital Partners 获取，地址为纽约，世界贸易中心 7 号，46 层，或通过电子邮件联系 capmarkets@konikcapitalpartners.com。</p>
<p>本新闻稿不构成出售或招揽购买本文所述证券的要约，也不应在任何州或其他司法管辖区进行这些证券的销售，除非在该州或其他司法管辖区的证券法下进行注册或资格认证。</p>
<p>除了注册直接发行外，公司还打算完成一项私人配售（“私人配售”），最多 571,428 股普通股，购买价格为每股 7.00 美元，预计总收益可达 400 万美元，面向某些加拿大买家进行私人配售。根据私人配售出售的普通股将受到四个月加一天的持有期限制，从私人配售的交割日期起算。私人配售的交割预计将在 2025 年 12 月 30 日之前进行，具体取决于公司获得所有必要的批准，包括多伦多证券交易所的有条件批准。私人配售下不会向美国买家出售任何证券，本新闻稿不构成在美国或任何其他司法管辖区出售或招揽购买此类证券的要约，除非在该司法管辖区的证券法下进行资格认证或注册。私人配售下所提供的证券尚未，也不会根据美国证券法进行注册，且在未注册或适用的美国注册要求和适用的美国州证券法的豁免情况下，这些证券不得在美国境内或向美国人士提供或出售。</p>
<p><strong>关于 Profound Medical Corp.</strong></p>
<p>Profound 是一家商业阶段的医疗设备公司，开发和销售基于人工智能的、MRI 引导的、无切口的疾病组织消融疗法。</p>
<p>Profound 正在商业化 TULSA-PRO®，这是一项结合实时 MRI、AI 增强规划、机器人驱动的经尿道超声和闭环温度反馈控制的技术。TULSA 程序™，使用 TULSA-PRO 系统进行，具有成为整个前列腺疾病谱系主流治疗方式的潜力；涵盖低、中、高风险前列腺癌；同时适用于同时患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；仅患有 BPH 的男性；以及需要针对放射复发局部前列腺癌进行挽救治疗的患者。TULSA 程序采用实时 MRI 引导，以精确保护患者的尿失禁和性功能，同时通过精确的声吸收技术将目标前列腺组织加热至 55-57°C。TULSA 是一种无切口、无辐射的 “一次性” 程序，在一个会话中完成，持续几个小时。几乎所有形状和大小的前列腺都可以安全、有效和高效地使用 TULSA 进行治疗。该程序没有出血；不需要住院；大多数 TULSA 患者报告迅速恢复到正常生活。TULSA-PRO 已获得 CE 标志、加拿大卫生部批准，并获得美国食品药品监督管理局（“FDA”）的 510(k) 清关。</p>
<p>Profound 还在商业化 Sonalleve®，这是一种创新的治疗平台，已获得 CE 认证，用于治疗子宫肌瘤、子宫腺肌症、骨转移疼痛缓解、纤维瘤和骨样骨瘤。Sonalleve 还获得了中国国家药品监督管理局的批准，用于非侵入性治疗子宫肌瘤，并在美国获得了人道主义设备豁免下的 FDA 批准，用于治疗骨样骨瘤。Profound 正在早期阶段探索 Sonalleve 的其他潜在治疗市场，该技术已显示出临床应用，例如非侵入性消融腹部癌症和癌症治疗的高温疗法。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告包含关于 Profound 及其业务的前瞻性声明，这些声明可能包括但不限于与公司预期收益使用、预计现金流和发行结束相关的声明。通常，但并不总是，前瞻性声明可以通过使用 “计划”、“预计”、“期望”、“安排”、“打算”、“考虑”、“预期”、“相信”、“提议” 或这些词语和短语的变体（包括否定变体）来识别，或声明某些行动、事件或结果 “可能”、“可以”、“将”、“可能” 或 “会” 被采取、发生或实现。这些声明基于 Profound 管理层的当前预期。本公告中讨论的前瞻性事件和情况，可能不会在某些特定日期或根本不发生，并可能因影响公司的已知和未知风险因素和不确定性而有实质性差异，包括计划的私募配售。尽管 Profound 已尝试识别可能导致实际行动、事件或结果与前瞻性声明中描述的内容有实质性差异的重要因素，但可能还有其他因素导致行动、事件或结果与预期、估计或意图的内容不同。没有任何前瞻性声明可以得到保证。可能导致实际结果与前瞻性声明中所列内容有实质性差异的其他因素和风险在 Profound 的 10-K 表格年度报告及其他向美国和加拿大证券监管机构提交的文件中进行了描述，相关文件可在 www.sedarplus.ca 和 www.sec.gov 获取。除非适用的证券法要求，前瞻性声明仅在作出时有效，Profound 不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，除非法律要求。</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p>Stephen Kilmer</p>
<p>投资者关系</p>
<p>skilmer@profoundmedical.com</p>
<p>电话：647.872.4849</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URXpOaU0zTXpNd05UYzRJekl3TVRnMU5EYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URXpOaU0zTXpNd05UYzRJekl3TVRnMU5EYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGUyZmJhMzgtZDg2NS00NzU0LTk5ZDAtZTEyMjZlYjI4ZmY1LTEwMzAxMTktMjAyNS0xMi0xOS1lbg==/tiny/Profound-Medical-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGUyZmJhMzgtZDg2NS00NzU0LTk5ZDAtZTEyMjZlYjI4ZmY1LTEwMzAxMTktMjAyNS0xMi0xOS1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

PROF

<p>Profound Medical Corp. 宣布进行 4000 万美元的融资，其中包括 3600 万美元的注册直接发行和 400 万美元的私募。此次发行涉及医疗保健投资者和现有股东，所得款项将用于销售扩展、研发和公司用途。直接发行预计将在 2025 年 12 月 22 日完成，私募预计在 2025 年 12 月 30 日完成，需获得相关批准。该公司开发基于人工智能的 MRI 引导疗法用于前列腺疾病治疗</p>

<p><strong>Financing included participation by healthcare-dedicated investors alongside existing shareholders</strong></p>
<div class="lb-trans"><p><strong>融资包括医疗专注投资者与现有股东的参与</strong></p>
</div><p>TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- <strong>Profound Medical Corp. (Nasdaq:PROF; TSX:PRN)</strong> (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase price of $7.00 per share for aggregate gross proceeds of up to $40 million.</p>
<div class="lb-trans"><p>多伦多，2025 年 12 月 19 日（GLOBE NEWSWIRE）-- <strong>Profound Medical Corp.（纳斯达克：PROF；多伦多证券交易所：PRN）</strong>（“Profound” 或 “公司”）今天宣布以每股 7.00 美元的价格出售 5,142,857 股普通股，进行注册直接发行，并计划在加拿大进行后续私人配售，最多 571,428 股普通股，购买价格为每股 7.00 美元，预计总收益可达 4000 万美元。</p>
</div><p>The registered direct offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders. This portion of the offering is expected to close on or about Monday, December 22, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>此次注册直接发行被结构化为一种简单的股权投资，没有认股权证覆盖，由医疗专注投资者与现有股东共同主导。该部分发行预计将在 2025 年 12 月 22 日（星期一）左右完成，具体取决于满足惯常的交割条件。</p>
</div><p>Gross proceeds to the Company from the offering are expected to be approximately $36 million, before deducting placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for expansion of its sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.</p>
<div class="lb-trans"><p>公司预计此次发行的总收益约为 3600 万美元，未扣除配售代理费用和公司需支付的其他发行费用。公司打算将发行的净收益用于销售和市场扩展、营运资金、研发、战略交易和一般公司用途。</p>
</div><p><strong>Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC, is acting as the exclusive placement agent for this offering.</strong></p>
<div class="lb-trans"><p><strong>Konik Capital Partners, LLC，T.R. Winston and Company, LLC 的一个部门，作为此次发行的独家配售代理。</strong></p>
</div><p>This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291516) which was previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on December 4, 2025. The offering is being made only by means of a prospectus supplement and accompanying base prospectus which form a part of the effective shelf registration statement. A prospectus supplement and the accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained, when available, from Konik Capital Partners, 7 World Trade Center, 46th Floor, New York, NY, or by email at capmarkets@konikcapitalpartners.com.</p>
<div class="lb-trans"><p>此次发行是根据已生效的 S-3 表格（文件编号 333-291516）进行的，该表格已于 2025 年 12 月 4 日向证券交易委员会（“SEC”）提交并获得批准。此次发行仅通过补充招股说明书和附带的基础招股说明书进行，这些文件构成有效的架构注册声明的一部分。与此次发行相关的补充招股说明书和附带的基础招股说明书将提交给 SEC，并可在 SEC 网站 http://www.sec.gov 上获取。此外，当可用时，补充招股说明书和附带的基础招股说明书的电子副本可从 Konik Capital Partners 获取，地址为纽约，世界贸易中心 7 号，46 层，或通过电子邮件联系 capmarkets@konikcapitalpartners.com。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售或招揽购买本文所述证券的要约，也不应在任何州或其他司法管辖区进行这些证券的销售，除非在该州或其他司法管辖区的证券法下进行注册或资格认证。</p>
</div><p>In addition to the registered direct offering, the Company intends to complete a private placement (the “Private Placement”) of up to 571,428 common shares at a purchase price of $7.00 per share, for aggregate gross proceeds of up to $4 million, to certain Canadian purchasers on a private placement basis. The common shares sold pursuant to the Private Placement will be subject to a hold period of four months plus one day from the closing date of the Private Placement. The closing of the Private Placement is expected to occur on or prior to December 30, 2025 and is subject to the Company receiving all necessary approvals, including the conditional approval from the Toronto Stock Exchange. No securities will be sold under the Private Placement to United States purchasers and this press release is not an offer to sell or the solicitation of an offer to buy such securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered under the Private Placement have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.</p>
<div class="lb-trans"><p>除了注册直接发行外，公司还打算完成一项私人配售（“私人配售”），最多 571,428 股普通股，购买价格为每股 7.00 美元，预计总收益可达 400 万美元，面向某些加拿大买家进行私人配售。根据私人配售出售的普通股将受到四个月加一天的持有期限制，从私人配售的交割日期起算。私人配售的交割预计将在 2025 年 12 月 30 日之前进行，具体取决于公司获得所有必要的批准，包括多伦多证券交易所的有条件批准。私人配售下不会向美国买家出售任何证券，本新闻稿不构成在美国或任何其他司法管辖区出售或招揽购买此类证券的要约，除非在该司法管辖区的证券法下进行资格认证或注册。私人配售下所提供的证券尚未，也不会根据美国证券法进行注册，且在未注册或适用的美国注册要求和适用的美国州证券法的豁免情况下，这些证券不得在美国境内或向美国人士提供或出售。</p>
</div><p><strong>About Profound Medical Corp.</strong></p>
<div class="lb-trans"><p><strong>关于 Profound Medical Corp.</strong></p>
</div><p>Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.</p>
<div class="lb-trans"><p>Profound 是一家商业阶段的医疗设备公司，开发和销售基于人工智能的、MRI 引导的、无切口的疾病组织消融疗法。</p>
</div><p>Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).</p>
<div class="lb-trans"><p>Profound 正在商业化 TULSA-PRO®，这是一项结合实时 MRI、AI 增强规划、机器人驱动的经尿道超声和闭环温度反馈控制的技术。TULSA 程序™，使用 TULSA-PRO 系统进行，具有成为整个前列腺疾病谱系主流治疗方式的潜力；涵盖低、中、高风险前列腺癌；同时适用于同时患有前列腺癌和良性前列腺增生（“BPH”）的混合患者；仅患有 BPH 的男性；以及需要针对放射复发局部前列腺癌进行挽救治疗的患者。TULSA 程序采用实时 MRI 引导，以精确保护患者的尿失禁和性功能，同时通过精确的声吸收技术将目标前列腺组织加热至 55-57°C。TULSA 是一种无切口、无辐射的 “一次性” 程序，在一个会话中完成，持续几个小时。几乎所有形状和大小的前列腺都可以安全、有效和高效地使用 TULSA 进行治疗。该程序没有出血；不需要住院；大多数 TULSA 患者报告迅速恢复到正常生活。TULSA-PRO 已获得 CE 标志、加拿大卫生部批准，并获得美国食品药品监督管理局（“FDA”）的 510(k) 清关。</p>
</div><p>Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.</p>
<div class="lb-trans"><p>Profound 还在商业化 Sonalleve®，这是一种创新的治疗平台，已获得 CE 认证，用于治疗子宫肌瘤、子宫腺肌症、骨转移疼痛缓解、纤维瘤和骨样骨瘤。Sonalleve 还获得了中国国家药品监督管理局的批准，用于非侵入性治疗子宫肌瘤，并在美国获得了人道主义设备豁免下的 FDA 批准，用于治疗骨样骨瘤。Profound 正在早期阶段探索 Sonalleve 的其他潜在治疗市场，该技术已显示出临床应用，例如非侵入性消融腹部癌症和癌症治疗的高温疗法。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, statements relating to the Company’s anticipated use of proceeds, expected cash runway and the closing of the offering. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including the planned Private Placement. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.</p>
<div class="lb-trans"><p>本公告包含关于 Profound 及其业务的前瞻性声明，这些声明可能包括但不限于与公司预期收益使用、预计现金流和发行结束相关的声明。通常，但并不总是，前瞻性声明可以通过使用 “计划”、“预计”、“期望”、“安排”、“打算”、“考虑”、“预期”、“相信”、“提议” 或这些词语和短语的变体（包括否定变体）来识别，或声明某些行动、事件或结果 “可能”、“可以”、“将”、“可能” 或 “会” 被采取、发生或实现。这些声明基于 Profound 管理层的当前预期。本公告中讨论的前瞻性事件和情况，可能不会在某些特定日期或根本不发生，并可能因影响公司的已知和未知风险因素和不确定性而有实质性差异，包括计划的私募配售。尽管 Profound 已尝试识别可能导致实际行动、事件或结果与前瞻性声明中描述的内容有实质性差异的重要因素，但可能还有其他因素导致行动、事件或结果与预期、估计或意图的内容不同。没有任何前瞻性声明可以得到保证。可能导致实际结果与前瞻性声明中所列内容有实质性差异的其他因素和风险在 Profound 的 10-K 表格年度报告及其他向美国和加拿大证券监管机构提交的文件中进行了描述，相关文件可在 www.sedarplus.ca 和 www.sec.gov 获取。除非适用的证券法要求，前瞻性声明仅在作出时有效，Profound 不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，除非法律要求。</p>
</div><p><strong>For further information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p>Stephen Kilmer</p>
<div class="lb-trans"><p>Stephen Kilmer</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>skilmer@profoundmedical.com</p>
<div class="lb-trans"><p>skilmer@profoundmedical.com</p>
</div><p>T: 647.872.4849</p>
<div class="lb-trans"><p>电话：647.872.4849</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URXpOaU0zTXpNd05UYzRJekl3TVRnMU5EYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNTEzNiM3MzMwNTc4IzIwMTg1NDc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGUyZmJhMzgtZDg2NS00NzU0LTk5ZDAtZTEyMjZlYjI4ZmY1LTEwMzAxMTktMjAyNS0xMi0xOS1lbg==/tiny/Profound-Medical-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MGUyZmJhMzgtZDg2NS00NzU0LTk5ZDAtZTEyMjZlYjI4ZmY1LTEwMzAxMTktMjAyNS0xMi0xOS1lbg==/tiny/Profound-Medical-Inc-.png"/></p>

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement | PROF Stock News

Profound Medical Corp.宣布定价高达 4000 万美元的融资计划，其中包括 3600 万美元的注册直接发行和随后 400 万美元的私人配售 | PROF 股票新闻